Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients - Top-Institutions - MDSpire

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • By

  • May Ee Png

  • Victoria Harris

  • Ly-Mee Yu

  • Paul Little

  • F. D. Richard Hobbs

  • Christopher C. Butler

  • Stavros Petrou

  • PANORAMIC Trial Collaborative Group

  • Oghenekome A Gbinigie

  • Najib M Rahman

  • Gail Hayward

  • Duncan B Richards

  • Jienchi Dorward

  • David M Lowe

  • Joseph F Standing

  • Judith Breuer

  • Saye Khoo

  • Kerenza Hood

  • Jonathan S Nguyen-Van-Tam

  • Mahendra G Patel

  • Benjamin R Saville

  • Joe Marion

  • Nick Francis

  • Nicholas P B Thomas

  • Philip Evans

  • Melissa Dobson

  • Jane Holmes

  • Mark Lown

  • Oliver van Hecke

  • Michelle A Detry

  • Christina T Saunders

  • Mark Fitzgerald

  • Nicholas S Berry

  • Sam Mort

  • Bhautesh D Jani

  • Nigel D Hart

  • Haroon Ahmed

  • Daniel Butler

  • Micheal McKenna

  • Lucy Cureton

  • Meena Patil

  • Monique Andersson

  • Clare Bateman

  • Jennifer C Davies

  • Andrew Ustianowski

  • Andrew Carson Stevens

  • May 6, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Platform Adaptative Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC)
    Platform Adaptative Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC)

    N/A, N/A

    Key Differentiators

    • Infectious Disease

  • #2

    National Health Service (NHS)
    National Health Service (NHS)

    London, England

    Key Differentiators

    • Public Health

  • #3

    National Institute for Health and Care Excellence (NICE)
    National Institute for Health and Care Excellence (NICE)

    London, England

    Key Differentiators

    • Health Economics

  • #4

    South Central-Berkshire Research Ethics Committee
    South Central-Berkshire Research Ethics Committee

    N/A, N/A

    Key Differentiators

    • Ethics

  • #5

    University Hospital Bonn
    University Hospital Bonn

    Bonn, Germany

    Key Differentiators

    • Infectious Disease

Original Source(s)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients

  • by May Ee Png, Victoria Harris, Ly-Mee Yu, Paul Little, F. D. Richard Hobbs, Christopher C. Butler, Stavros Petrou, PANORAMIC Trial Collaborative Group, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Jane Holmes, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Lucy Cureton, Meena Patil, Monique Andersson, Clare Bateman, Jennifer C Davies, Andrew Ustianowski, Andrew Carson Stevens

  • May 6, 2026

Related Content

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

Human Papillomavirus Vaccine Discourse and Sentiment on Reddit Before and After COVID-19: Mixed Methods Retrospective Cross-Sectional Study

Complement activation in patients with post-acute sequelae after SARS-CoV-2 infection